ライフサイエンスコーパス: spondyloarthropathy

1 rthropathy, psoriatic arthritis and juvenile spondyloarthropathy.

2 e use of ultrasound imaging in patients with spondyloarthropathy.

3 ion of disease in patients with seronegative spondyloarthropathy.

4 control of chronic uveitis in patients with spondyloarthropathy.

5 re was no improvement in symptoms related to spondyloarthropathy.

6 eing investigated in the various subtypes of spondyloarthropathy.

7 may be part of a systemic illness such as a spondyloarthropathy.

8 as well as specifically, in association with spondyloarthropathy.

9 yloarthropathies, including 80 with juvenile spondyloarthropathy.

10 d enthesitis, is a characteristic feature of spondyloarthropathy.

11 ciated with a group of human diseases called spondyloarthropathies.

12 rthropathies (SpAs), particularly peripheral spondyloarthropathies.

13 of eye disease in patients with seronegative spondyloarthropathies.

14 often effective for uveitis associated with spondyloarthropathies.

15 tations in patients affected by seronegative spondyloarthropathies.

16 has proven very successful for patients with spondyloarthropathies.

17 icularly those with rheumatoid arthritis and spondyloarthropathies.

18 lation of psoriatic arthritis with the other spondyloarthropathies.

19 hypothesis concerning the role of B27 in the spondyloarthropathies.

20 l system, including rheumatoid arthritis and spondyloarthropathies.

21 ther investigation of the role of HLA-B27 in spondyloarthropathies.

22 the classification and treatment of juvenile spondyloarthropathies.

23 e detection of sacroiliitis in children with spondyloarthropathies.

24 eviews the recent literature on the juvenile spondyloarthropathies.

25 lications for the mechanisms of synovitis in spondyloarthropathies.

26 n the HLA-B27 B pocket and susceptibility to spondyloarthropathies.

27 e of bone changes seen in some patients with spondyloarthropathies.

28 itis, juvenile rheumatoid arthritis, and the spondyloarthropathies.

29 n (Tap/Lmp), have been postulated in certain spondyloarthropathies.

30 ed the association between HLA-B27 and human spondyloarthropathies.

31 tive in psoriasis, with promising results in spondyloarthropathies also emerging.

32 bility to ankylosing spondylitis and related spondyloarthropathies, although the underlying molecular

33 is association varies markedly among various spondyloarthropathies and among ethnic groups.

34 s strongly associated with susceptibility to spondyloarthropathies and can cause arthritis when expre

35 rolling uveitis associated with seronegative spondyloarthropathies and juvenile idiopathic arthritis;

36 rs of multiple diseases including psoriasis, spondyloarthropathy and multiple sclerosis.

37 erlying process of inflammatory arthritis in spondyloarthropathy and other inflammatory arthritides.

38 disease, juvenile dermatomyositis, juvenile spondyloarthropathy and systemic vascular disease.

39 hritis, reactive arthritis, undifferentiated spondyloarthropathy, and arthritis associated with infla

40 able among controls and individuals with RA, spondyloarthropathy, and CPPD.

41 arthritis, systemic lupus erythematosus and spondyloarthropathy, and preclinical models suggest that

42 severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patients requiring

43 tory arthritides included in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic a

44 Spondyloarthropathies are a cluster of interrelated and

45 The spondyloarthropathies are a group of conditions which sh

46 The seronegative spondyloarthropathies are a group of disorders sharing c

47 The spondyloarthropathies are a group of rheumatic diseases

48 Spondyloarthropathies are closely related to genetics an

49 ing recognition of the natural course of the spondyloarthropathies are leading to a more rational the

50 Although spondyloarthropathies are not associated with rheumatoid

51 Spondyloarthropathies belong to a group of rheumatic dis

52 HLA-B27 is highly associated with the human spondyloarthropathies, but the basis for this associatio

53 ssociated with the rheumatic diseases termed spondyloarthropathies, but the mechanism is not known.

54 The spondyloarthropathy classification criteria continue to

55 is, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Perman

56 gic research relevant to the pathogenesis of spondyloarthropathies concerns the relationship between

57 nic arthritis, including those with juvenile spondyloarthropathy, concluded that it was safe and effe

58 In case of other types of spondyloarthropathies diagnosis is made based on presenc

59 on to the ubiquitous nature of enthesitis in spondyloarthropathies, especially adjacent to synovial j

60 both adult and juvenile disease criteria for spondyloarthropathy exist, the place of psoriatic arthri

61 tis constitutes a discreet subset within the spondyloarthropathy group, but the demarcation continues

62 Although association of HLA-B27 with human spondyloarthropathies has been known for several years,

63 ce of enthesitis as a skeletal phenomenon in spondyloarthropathies has gained further support from tr

64 , HLA-B27, which is strongly associated with spondyloarthropathy, has also been shown to stimulate IL

65 Topics relating to the spondyloarthropathies have been reviewed recently, but t

66 The mediators of inflammation in spondyloarthropathies have begun to be elucidated.

67 diseases, including rheumatoid arthritis and spondyloarthropathies, have been critical for identifica

68 nd specific for identifying undifferentiated spondyloarthropathies in adults have been developed, and

69 uence of HIV infection on the development of spondyloarthropathies in Africa.

70 A second theme has come from the study of spondyloarthropathies in different ethnic groups and soc

71 physical activity in patients with juvenile spondyloarthropathy in remission and suggested a decline

72 This is especially relevant in the case of spondyloarthropathy in which case prevention of the nove

73 Pathogenesis of spondyloarthropathy, in particular the part played by HL

74 s emphasized clinical characteristics of the spondyloarthropathies including reactive arthritis.

75 und in a Mexican population of patients with spondyloarthropathies, including 80 with juvenile spondy

76 nt progress in disease-modifying therapy for spondyloarthropathy, including new biologic response mod

77 e influence of HLA-B27 on the development of spondyloarthropathies is undisputed, its role in pathoge

78 to appear in swollen joints associated with spondyloarthropathy is an enthesitis (inflammation at si

79 We propose that the synovitis of spondyloarthropathy is secondary to liberation of proinf

80 ary synovial (rheumatoid-like) or entheseal (spondyloarthropathy-like) and allows differentiation of

81 on of a polyarthritis with a good prognosis (spondyloarthropathy-like), from that with a bad prognosi

82 10,484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha anta

83 ive individuals with documented RA (n = 15), spondyloarthropathy (n = 15), and calcium pyrophosphate

84 Spondyloarthropathies occur in genetically predisposed p

85 uding rheumatoid arthritis, Crohn's disease, spondyloarthropathies, psoriasis and allograft rejection

86 inumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosin

87 isease, reactive arthritis, undifferentiated spondyloarthropathy, psoriatic arthritis and juvenile sp

88 Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antago

89 stions concerning classification of juvenile spondyloarthropathies remain unresolved.

90 The taxonomy of juvenile spondyloarthropathy remains a contentious issue, and fur

91 The spondyloarthropathies (SpAs) are a group of interrelated

92 t common group of rheumatoid disorders, i.e. spondyloarthropathies (SpAs), particularly peripheral sp

93 usceptibility to a group of disorders termed spondyloarthropathies (SpAs).

94 The predictive value of the European Spondyloarthropathy Study Group criteria for spondyloart

95 classification criterion, from the European Spondyloarthropathy Study Group, encompasses the current

96 h bone proliferation suggests a seronegative spondyloarthropathy, such as psoriatic arthritis, reacti

97 on of IL-23 biology is a unifying feature of spondyloarthropathy, suggesting that treatments targetin

98 We have included studies on adult onset spondyloarthropathies that are particularly relevant to

99 p a spontaneous disease resembling the human spondyloarthropathies that includes arthritis and coliti

100 ive arthritis (ReA) is an HLA-B27-associated spondyloarthropathy that is triggered by diverse bacteri

101 g more like rheumatic fever and a group with spondyloarthropathy traits.

102 Spondyloarthropathy Study Group criteria for spondyloarthropathy varies with the prevalence of the di

103 of juvenile arthritis including the juvenile spondyloarthropathies was investigated and suggested a r

104 systemic lupus erythematosus, as well as the spondyloarthropathies which more closely resemble the au

105 lar therapeutic challenges are raised by the spondyloarthropathies which represent a key area of unme

106 SAS discusses only the classic form of axial spondyloarthropathies, which is ankylosing spondylitis.

107 ation, published classification criteria for spondyloarthropathies, which propose standardization of

108 the connection between gut inflammation and spondyloarthropathy--which has been carefully documented

109 In arthritis of the axial skeleton, mainly spondyloarthropathies, whole-body MR imaging reveals add

110 ution to the problem of the association of a spondyloarthropathy with several